CollPlant Biotechnologies (CLGN) Q3 2024 earnings summary

Executive summary

• Advanced preclinical studies for rhCollagen-based breast implants showed significant vascularization, rapid tissue ingrowth, and safety, advancing toward human trials.

• Collaboration with AbbVie continues on dermal and soft tissue filler products, with $24 million in milestone payments to date and eligibility for up to $50 million.

• Partnership with Stratasys focuses on scalable 3D bioprinting for regenerative breast implants, targeting a $3 billion market.

• Ongoing efforts to secure non-dilutive funding through new partnerships and operational streamlining.

• Presented technology at the International Society for Biofabrication, generating new collaboration opportunities.

Financial highlights

• Q3 2024 GAAP revenue was $4,000, down from $43,000 in Q3 2023, mainly due to timing of rhCollagen deliveries.

• Nine-month 2024 GAAP revenue was $351,000, down from $10.7 million in 2023, reflecting a $10 million milestone payment in the prior year.

• Q3 2024 GAAP net loss was $4.3 million ($0.38/share); nine-month net loss was $12.7 million ($1.11/share).

• Q3 2024 non-GAAP net loss was $3.8 million ($0.33/share); nine-month non-GAAP net loss was $11.5 million ($1.00/share).

• Cash and cash equivalents as of September 30, 2024, were $15.4 million, down from $26.7 million at year-end 2023, expected to fund operations through 2025.

Outlook and guidance

• Focus on advancing dermal filler program with AbbVie and generating more data for breast implant clinical studies.

• Targeting new collaboration agreements in 2025 to secure additional non-dilutive funding.

• Further preclinical breast implant results anticipated in Q1 2025.

• Continued discussions with industry leaders for rhCollagen applications and technology partnerships.